{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:43:24Z","timestamp":1789879404390,"version":"4.0.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","funder":[{"name":"NCI","award":["N01-CP-11005"],"award-info":[{"award-number":["N01-CP-11005"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000124","name":"Office of Research on Women's Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000124","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GlaxoSmithKline Biologicals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,5]]},"DOI":"10.1093\/infdis\/jiy112","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T06:55:35Z","timestamp":1523516135000},"page":"84-94","source":"Crossref","is-referenced-by-count":27,"title":["Risk of HPV-16\/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials"],"prefix":"10.1093","volume":"218","author":[{"given":"Mahboobeh","family":"Safaeian","sequence":"first","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Castellsagu\u00e9","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Research Program, Catalan Institute of Oncology, Institut d'Investigaci\u00f3 Biom\u00e9dica de Bellvitge, L\u2019Hospitalet de Llobregat, Catalonia, Spain"},{"name":"Centros de Investigaci\u00f3n Biom\u00e9dica en Red, Epidemiolog\u00eda y Salud P\u00fablica, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Hildesheim","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sholom","family":"Wacholder","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H","family":"Schiffman","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-C\u00e9cile","family":"Bozonnat","sequence":"additional","affiliation":[{"name":"Clinics, Paris, France, GlaxoSmithKline, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Baril","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Rosillon","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Costa Rica HPV Vaccine Trial and the PATRICIA study groups","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S-N","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"De Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Del Rosario","family":"Raymundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F Diaz","family":"Mitoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Dubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Garland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Germar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D M","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Jaisamrarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A R","family":"Kreimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Lehtinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Naud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Paavonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Poppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Porras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Salmer\u00f2n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S R","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Struyf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Tjalma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,30]]},"reference":[{"key":"key\n\t\t\t\t20180626074819_CIT0001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"key\n\t\t\t\t20180626074819_CIT0002","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJM199911253412201","article-title":"Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer","volume":"341","author":"Wallin","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180626074819_CIT0003","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199210293271804","article-title":"A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection","volume":"327","author":"Koutsky","year":"1992","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180626074819_CIT0004","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens\u2013Part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180626074819_CIT0005","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180626074819_CIT0006","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ijc.27713","article-title":"Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe","volume":"132","author":"Tjalma","year":"2013","journal-title":"Int J Cancer"},{"key":"key\n\t\t\t\t20180626074819_CIT0007","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1086\/315086","article-title":"Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer","volume":"180","author":"Franco","year":"1999","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626074819_CIT0008","first-page":"421","article-title":"Incidence, clearance and predictors of human papillomavirus infection in women","volume":"168","author":"Sellors","year":"2003","journal-title":"CMAJ"},{"key":"key\n\t\t\t\t20180626074819_CIT0009","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/jnci\/djq001","article-title":"Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2\/3: critical role of duration of infection","volume":"102","author":"Rodr\u00edguez","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20180626074819_CIT0010","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jnci\/djn044","article-title":"Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections","volume":"100","author":"Rodr\u00edguez","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20180626074819_CIT0011","doi-asserted-by":"crossref","first-page":"e79260","DOI":"10.1371\/journal.pone.0079260","article-title":"Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study","volume":"8","author":"Jaisamrarn","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180626074819_CIT0012","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/OLQ.0b013e3181e1a2c5","article-title":"Seroprevalence and correlates of human papillomavirus 16\/18 seropositivity among young women in Costa Rica","volume":"37","author":"Coseo","year":"2010","journal-title":"Sex Transm Dis"},{"key":"key\n\t\t\t\t20180626074819_CIT0013","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/jnci\/86.7.494","article-title":"A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16","volume":"86","author":"Kirnbauer","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20180626074819_CIT0014","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1128\/CDLI.4.2.122-126.1997","article-title":"Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women","volume":"4","author":"Viscidi","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"key\n\t\t\t\t20180626074819_CIT0015","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626074819_CIT0016","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180626074819_CIT0017","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/342972","article-title":"Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles","volume":"186","author":"Ho","year":"2002","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626074819_CIT0018","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1055-9965.EPI-03-0166","article-title":"Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica","volume":"13","author":"Viscidi","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key\n\t\t\t\t20180626074819_CIT0019","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/1055-9965.283.14.1","article-title":"Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women","volume":"14","author":"Viscidi","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key\n\t\t\t\t20180626074819_CIT0020","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Hum Vaccin"},{"key":"key\n\t\t\t\t20180626074819_CIT0021","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/jnci\/djq384","article-title":"Epidemiological study of anti-HPV16\/18 seropositivity and subsequent risk of HPV16 and -18 infections","volume":"102","author":"Safaeian","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20180626074819_CIT0022","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/infdis\/jiu139","article-title":"Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16\/18 antibodies: analysis of the control arm of PATRICIA","volume":"210","author":"Castellsagu\u00e9","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626074819_CIT0023","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/infdis\/jir209","article-title":"A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study","volume":"204","author":"Wentzensen","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626074819_CIT0024","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180626074819_CIT0025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2159-8290.CD-11-0131","article-title":"Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica","volume":"1","author":"Herrero","year":"2011","journal-title":"Cancer Discov"},{"key":"key\n\t\t\t\t20180626074819_CIT0026","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/infdis\/jiu648","article-title":"Raising expectations for subunit vaccine","volume":"211","author":"Schiller","year":"2015","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626074819_CIT0027","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.4161\/hv.36121","article-title":"Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial","volume":"10","author":"Einstein","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t20180626074819_CIT0028","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1086\/599988","article-title":"Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials","volume":"200","author":"Schiller","year":"2009","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626074819_CIT0029","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1158\/1055-9965.EPI-12-0558","article-title":"Direct comparison of HPV16 serological assays used to define HPV-na\u00efve women in HPV vaccine trials","volume":"21","author":"Safaeian","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key\n\t\t\t\t20180626074819_CIT0030","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3389\/fonc.2013.00328","article-title":"Comparison of antibody responses to human papillomavirus vaccination as measured by three assays","volume":"3","author":"Robbins","year":"2014","journal-title":"Front Oncol"},{"key":"key\n\t\t\t\t20180626074819_CIT0031","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/infdis\/174.5.927","article-title":"The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women","volume":"174","author":"Carter","year":"1996","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180626074819_CIT0032","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4161\/hv.4.6.6912","article-title":"Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16\/18 cervical cancer vaccine","volume":"4","author":"Dessy","year":"2008","journal-title":"Hum Vaccin"},{"key":"key\n\t\t\t\t20180626074819_CIT0033","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1055-9965.EPI-09-1235","article-title":"Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women","volume":"19","author":"Insinga","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/218\/1\/84\/25091090\/jiy112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T02:39:54Z","timestamp":1660876794000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/218\/1\/84\/4990620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,30]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,4,30]]},"published-print":{"date-parts":[[2018,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiy112","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,7,1]]},"published":{"date-parts":[[2018,4,30]]}}}